Immunome (IMNM) Earnings Date, Estimates & Call Transcripts $12.55 -0.26 (-2.03%) (As of 10:14 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Immunome Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 14EstimatedActual EPS (Aug. 12) -$0.49 Missed By -$0.11 Consensus EPS (Aug. 12) -$0.38 Immunome announced Q2 2024 earnings on August 12, 2024, reporting an EPS of -$0.49, which missed the consensus estimate of -$0.38 by $0.11. Quarterly revenue was reported to be $2.36 million, below the consensus estimate of $2.62 million. With a trailing EPS of -$7.69, Immunome's earnings are expected to decrease next year, from ($1.92) to ($3.04) per share. IMNM Upcoming EarningsImmunome's next earnings date is estimated for Thursday, November 14, 2024, based off prior year's reporting schedules. Get Immunome Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIMNM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IMNM Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Huge AlertsNASDAQ traded stock with a BIG short position. Small cap NASDAQ firm is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!See how this NASDAQ Bio-tech is offering viable solutions Immunome Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$1.63-$0.52-$1.08Q2 20242-$0.57-$0.18-$0.38Q3 20242-$0.77-$0.53-$0.65Q4 20242-$0.81-$0.50-$0.66FY 20248-$3.78-$1.73-$2.76Q1 20251-$0.99-$0.99-$0.99Q2 20251-$0.96-$0.96-$0.96Q3 20251-$1.00-$1.00-$1.00Q4 20251-$1.02-$1.02-$1.02FY 20254($3.97)($3.97)($3.97) Immunome Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/12/2024Q2 2024-$0.38-$0.49 -$0.11-$0.38$2.62M$2.36M5/14/2024Q1 2024-$0.80-$0.34+$0.46$1.83$4.00M$1.03M 3/28/2024Q4 2023-$0.28-$0.54 -$0.26$3.14$3.40M$3.83M 11/9/2023Q3 2023--$0.36 -$0.36-$0.36-$3.57M 8/9/2023Q2 2023--$0.46 -$0.46-$0.46-$4.26M 5/5/2023Q1 2023--$0.35 -$0.35-$0.35-$2.36M Get the Latest News and Ratings for IMNM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. 3/16/2023Q4 2022--$0.64 -$0.64-$0.64-- 11/14/2022Q3 2022--$0.75 -$0.75-$0.75-- Immunome Earnings - Frequently Asked Questions When is Immunome's earnings date? Immunome has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on IMNM's earnings history. Did Immunome beat their earnings estimates last quarter? In the previous quarter, Immunome (NASDAQ:IMNM) missed the analysts' consensus estimate of ($0.38) by $0.11 with a reported earnings per share (EPS) of ($0.49). Learn more on analysts' earnings estimate vs. IMNM's actual earnings. How much revenue does Immunome generate each year? Immunome (NASDAQ:IMNM) has a recorded annual revenue of $14.02 million. How much profit does Immunome generate each year? Immunome (NASDAQ:IMNM) has a recorded net income of -$106.81 million. IMNM has generated -$7.69 earnings per share over the last four quarters. What is Immunome's EPS forecast for next year? Immunome's earnings are expected to decrease from ($1.92) per share to ($3.04) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies IGM Biosciences Earnings Vir Biotechnology Earnings Enlivex Therapeutics Earnings Verona Pharma Earnings Protagonist Therapeutics Earnings Amneal Pharmaceuticals Earnings Catalyst Pharmaceuticals Earnings Agios Pharmaceuticals Earnings Amphastar Pharmaceuticals Earnings ACADIA Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run NASDAQ traded stock with a BIG short position. (Ad)Small cap NASDAQ firm is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!See how this NASDAQ Bio-tech is offering viable solutions This page (NASDAQ:IMNM) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNM Stock Alerts